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A
lthough the genomic sciences emerged from squarely 
within the biological sciences, genomics and biology 
often now seem almost strangers. Nowhere is this 
divide more striking, or more unfortunate, than in studies 
of the genetics of complex traits such as common human 
diseases.
For many years, attempts at understanding the genetics 
of common diseases languished in candidate gene studies 
that identiﬁed risk alleles (or gene variants) that were 
notorious for their reluctance to replicate an association 
in other studies, or in linkage peaks that either failed to 
replicate or failed to resolve to individual chromosomal 
loci. As recently as 2002, Glazier et al. lamented the 
contrast between the rapid elucidation of the genetic 
bases of Mendelian diseases, which involve mutations in 
single genes, and the paltry returns for the complex, or 
multifactorial traits, including most common diseases [1], 
which involve obscure interactions between variant alleles 
at multiple genomic locations. Now all that has changed. A 
recent unpublished review of the literature revealed over 50 
genome scans for common diseases and other complex traits 
that can be considered to have securely identiﬁed almost 
100 independent genetic polymorphisms associated with 
speciﬁc human traits, mostly common diseases. While other 
variants show suggestive associations, these ~100 variants 
show an association p-value of ≤10
8, meaning that the level 
of association is robust even after taking into account all the 
hypotheses (i.e., independent polymorphisms) that must be 
tested when the genome as a whole is mined for common 
variants that inﬂuence disease. Most of these identiﬁed 
variants therefore are real risk factors with real health 
implications.
That is the good news. The bad news is that we know almost 
nothing about the biological roles of the implicated variants. 
Indeed, in most cases what has been identiﬁed is a genomic 
region with multiple polymorphisms showing some degree of 
association, but without any clarity about which variant in the 
region is causally responsible. What is even more troubling 
than the dearth of biological insight is the mismatch in effort 
between discovery of these associated regions and signiﬁcant 
biological experimentation designed to identify the causal 
variants and understand their underlying contributions to 
disease pathophysiology. 
I should clarify here what is, at least to me, the appropriate 
role for biology in the interpretation of association results. In 
the pregenomics era, arguments of biological plausibility were 
marshaled with prodigious creativity to argue that modest 
association results should be accepted as real because they 
“make biological sense.” With few exceptions, this sort of 
theorizing led to catastrophe. This use of biological insight is 
as tempting as the Sirens singing from the coast of Sirenum; 
the only sure passage is either to plug your ears, or else to 
follow Odysseus and listen, but remain bound tightly to 
the mast of genome-wide signiﬁcance and thus pass safely 
through.
But once an association is clearly established, it is time to 
return to biology and do whatever is needed to understand 
the association. One area that stands out for its consistent 
and helpful use of biological experiments to reveal the 
biological underpinning of an association is the study of 
infectious disease, particularly HIV. All anti-HIV drugs are 
“smart drugs” designed to target speciﬁc aspects of the 
HIV life cycle. Similar biological research has been applied 
to the interpretation of association results between host 
genetic factors and the control of HIV. For example, the 
human genetic variant HLA-B*5701 is one of the most 
secure association results for a human complex trait and 
one of the best understood at a molecular level. Several 
HLA-B alleles are known to be associated with better control 
of HIV and delayed progression to AIDS (Box 1). These 
alleles, in particular HLA-B*5701, are also known to present 
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Box 1. HLA-B*5701
HLA-B, or human leukocyte antigen B, is a protein that plays 
a key role in the cellular component of adaptive immunity. 
HLA-B, along with related genes, is involved in presenting 
peptide fragments of intracellular pathogens on the surface of 
infected cells, thus triggering cellular-based immune attacks on 
the infected cells. HLA-B is one of the highly variable genes in 
the major histocompatibility complex region with a very high 
degree of polymorphism and many alleles of known functional 
signiﬁcance. Among the functional alleles at HLA-B, HLA-B*5701 
has been the most strongly associated with control of HIV. 
Interestingly, while patients carrying the HLA-B*5701 allele are 
better able to control HIV infection, they are also much more 
susceptible to hypersensitivity to one of the antiretroviral drugs 
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HIV epitopes on the surface of infected cells that are more 
effective in eliciting destruction by killer T cells [2]. Related 
work has even gone on to show that HIV responds to the 
selection imposed by B*5701 with escape mutations that allow 
the virus to evade presentation by B*5701 to immune cells 
[3].
The most recent example of the creative combination of 
genomics and biology comes from a study by Amalio Telenti 
and colleagues [4] on the determinants of human cells’ 
“permissiveness” to HIV in an in vitro assay. Broadly speaking, 
a human polymorphism may inﬂuence response to HIV in 
humans either through a direct mechanism, for example, 
by interfering with HIV entry to cells or replication within 
cells, or through an immune mechanism that helps the 
immune system destroy infected cells (or protect bystander 
noninfected cells from HIV-induced apoptosis). An example 
of the former category is the deletion in the CCR5 gene, 
which removes a protein from the cell surface that HIV uses 
to gain entry into cells, while an example of the latter is the 
HLA-B alleles described above. 
In vitro experiments, in particular monocellular assays 
excluding the possibility of immune-mediated effects, 
can help to disentangle these possible mechanisms. To 
search for gene variants that inﬂuence non-immune-
related mechanisms, Telenti and colleagues capitalized on 
the International HapMap Project, which has established 
genotype data for more than 3 million polymorphisms in 
270 individuals from populations with African, Asian, and 
European ancestry. The DNA samples for 90 individuals of 
European ancestry have been drawn from the Centre d’Etude 
du Polymorphisme Humain (CEPH) repository [4]. Cell 
samples are available from some of these same individuals in 
the CEPH repository, in particular immortalized B cells. It is 
therefore possible to carry out assays on these immortalized 
B cells and relate the results to the already available dense 
genotypic data generated and maintained by the HapMap 
Project (http://www.hapmap.org/). 
While B cells are not natural targets of HIV, and therefore 
cannot be directly infected with competent HIV virions, 
they can be used to assess some post-entry aspects of HIV 
replication within cells. Telenti and colleagues modiﬁed a 
commonly used viral vector to include key HIV genes and 
then used the modiﬁed vector to introduce the HIV genes to 
B cells. A reporter system was then used to assess important 
steps in the HIV life cycle, including reverse transcription 
(copying the HIV RNA sequences into DNA), integration of 
the retrotranscribed genes into the host cell genome, and 
then transcription and translation of the HIV genes into 
functional proteins. Telenti and colleagues ﬁrst showed that 
the trait under study, cell permissiveness to HIV, was heritable 
by studying correlations among the related CEPH individuals. 
They then used the extensive genotype data available for 
many of the CEPH individuals to carry out linkage and ﬁne 
mapping experiments, implicating a polymorphism on 
chromosome 8 in a cluster of genes not previously connected 
to HIV. Both the linkage and the ﬁne mapping data make a 
strong case that variation in this region is connected to host 
cell permissiveness under the conditions studied.
To assess whether the polymorphism also has an impact in 
vivo, they genotyped it in 805 HIV-positive individuals who 
were followed for at least seven years, but for whom the date 
of infection was unknown in most cases. They found that the 
allele conferring the most permissiveness in the cell system was 
modestly associated with higher viral load and faster progression 
to AIDS. A follow-up test in 189 individuals with a precise date 
of infection, however, failed to show the same effect.
While the linkage and ﬁne mapping in the B cells appears 
very solid, the in vivo association with a speciﬁc polymorphism 
remains equivocal. Moreover, as Telenti and colleagues show, 
the correlation between permissiveness in CD4 T cells (a 
natural HIV target) and B cells is clearly signiﬁcant, but far 
from complete—variation in B cell permissiveness explains 
only about half of the variation in T cell permissiveness. 
This suggests that there will be many factors that inﬂuence 
HIV permissiveness within B cells that do not translate to 
CD4-positive T cells and, thus, do not translate to in vivo 
control. Nevertheless, further support for a role of the 
neighboring genes has also been provided by a recent tour 
de force effort, in which Stephen Elledge and colleagues 
knocked down each of 21,121 human genes to see which was 
associated with cellular infectivity [5]. Of the 281 genes that 
were implicated, two were in the linkage region identiﬁed by 
Telenti and colleagues. 
Studies like those from the Telenti and Elledge groups and 
others can identify non-immune host factors that inﬂuence 
cellular infectivity. Other assays have been developed that 
can assess aspects of adaptive immunity in controlled settings 
and assess how genetic variation inﬂuences speciﬁc immune 
responses to HIV. As the genomics revolution continues to 
identify new determinants of responses to HIV and other 
infectious agents [6], novel experimental paradigms like 
those being pioneered by Telenti and Elledge and colleagues 
will be needed to determine how the polymorphisms exert 
their effects, and how any new mechanisms of control 
identiﬁed can help to combat HIV/AIDS.  
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